



ERIC HOLCOMB, GOVERNOR  
STATE OF INDIANA

*Office of Medicaid Policy and Planning*  
MS 07, 402 W. WASHINGTON STREET, ROOM W382  
INDIANAPOLIS, IN 46204-2739

## MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee  
November 4, 2022  
9 A.M.

***Virtual Meeting - Microsoft Teams Link Provided Below***

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meeting of August 5, 2022
4. Preferred Drug List: Therapeutic Class Re-Review
  - a) CNS and Others
    - i. Agents for the Treatment of Opiate Addiction
    - ii. Antiemetic/Antivertigo Agents
    - iii. Antiseizure Agents
    - iv. Gastroprotective NSAIDs
    - v. Movement Disorder Agents
    - vi. Narcotic Antitussive/1<sup>st</sup> Generation Antihistamine Combinations
    - vii. Narcotics
    - viii. Skeletal Muscle Relaxants
    - ix. Smoking Deterrent Agents
  - b) Dermatologic Agents
    - i. Acne Agents
    - ii. Antipsoriatic Agents
  - c) Endocrine



- i. Anaphylaxis Agents
  - ii. Bone Formation Stimulating Agents
  - iii. Bone Resorption Inhibitors
  - iv. DPP-4 Inhibitors and Combination Agents
  - v. GLP-1 Receptor Agonists and Combinations
  - vi. Glucagon Agents
  - vii. Growth Hormones
  - viii. Injectable Hypoglycemics, Insulin
  - ix. Miscellaneous Oral Antidiabetic Agents
  - x. SGLT2 Inhibitors and Combinations
  - xi. Testosterones
- d) Estrogen and Related Agents
  - i. Estrogen and Related Agents
  - ii. Contraceptives
- e) Gastrointestinal Agents
  - i. Anti-ulcer Agents
  - ii. *H. Pylori* Agents
  - iii. H2 Receptor Antagonists
  - iv. Laxatives and Cathartics
  - v. Pancreatic Enzymes
  - vi. Proton Pump Inhibitors
  - vii. Ulcerative Colitis Agents
- f) Genitourinary Agents
  - i. Benign Prostatic Hypertrophy Agents
  - ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents
- g) Hematologic Agents
  - i. Direct Factor Xa Inhibitors
  - ii. Direct Thrombin Inhibitors
  - iii. Hematinics
  - iv. Leukocyte (WBC) Stimulants
  - v. Platelet Aggregation Inhibitors
- h) Targeted Immunomodulators

i) Topical Agents

- i. Dry Eye Disease or Keratoconjunctivitis
- ii. Miotics-Intraocular Pressure Reducers
- iii. Ophthalmic Antihistamines
- iv. Ophthalmic Anti-Inflammatory Agents
- v. Ophthalmic Mast Cell Stabilizers
- vi. Otic Preparations
- vii. Topical Anti-Inflammatory Agents-NSAIDs
- viii. Topical Antiparasitics
- ix. Topical Immunomodulators
- x. Topical Post-herpetic Neuralgia Agents

5. New Business

6. Public Comment

7. Other Business

8. Adjourn

---

## Microsoft Teams meeting

**Join on your computer, mobile app or room device**

[Click here to join the meeting](#)

Meeting ID: 220 774 592 539

Passcode: rRiAbL

[Download Teams](#) | [Join on the web](#)

**Join with a video conferencing device**

425899727@t.plcm.vc

Video Conference ID: 118 855 352 96

[Alternate VTC instructions](#)

**Or call in (audio only)**

[+1 952-222-7450,410522243#](#) United States, Bloomington

Phone Conference ID: 410 522 243#

[Find a local number](#) | [Reset PIN](#)